You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Actigraphy Enhanced Clinical Chronic Lower Back Pain Management
SBC: ARBOR MEDICAL INNOVATIONS LLC Topic: 105ABSTRACTEffective management of patients with chronic low back pain requires accurate and reliable methods to measure the effects of treatment on both pain and function. Yet this presents a serious dilemma to clinicians, who must currently rely exclusively on retrospective self-report measures (e.g., questionnaires) to capture this information. These assessments are usually only completed each tim ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome
SBC: MITOPOWER LLC Topic: 999Novel therapy for alcoholic liver disease-associated hepatorenal syndrome Abstract Alcoholic liver disease (ALD) results in over 400,000 hospitalizations each year in the US, with a portion of these patients developing hepatorenal syndrome with acute kidney injury (HRS-AKI). There are no current therapeutic options that specifically address the cellular dysfunction and systemic inflammatory respon ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain
SBC: NAVEGA THERAPEUTICS, INC. Topic: 107ABSTRACTChronic pain is pain that persists past the normal time of healing. 1.5 billion people worldwide suffer from chronic pain and this number continues to increase as the elderly population grows, the prevalence of diabetes rises, and cancer survival rates improve. Chronic pain not only severely impacts daily quality of life for many patients, it also places a heavy socioeconomic burden on soc ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A novel approach to restricting the spread of neurofibrillary tau
SBC: NOVORON BIOSCIENCE INC Topic: NIA7. Project Summary Alzheimer’s disease (AD) is the most common cause of dementia and is a growing problem as populations age. More than 25 million people are affected by dementia worldwide with most suffering from AD. AD is characterized by the presence of plaques of insoluble amyloid-beta (Aβ) and tangles of hyperphosphorylated aggregates of the cytoskeletal protein, tau. Thus far, most AD tre ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Plug-and-Play High-Order B0 Shimming for Reliable Temporal Lobe Epilepsy Magnetic Resonance Spectroscopic Imaging
SBC: LUCIDITY MEDICAL, LLC Topic: 103Abstract: Epilepsy affects 7 million people globally, and the temporal lobe epilepsy (TLE) is its most common form. For TLE patients that are undergoing surgical treatment, functional neuroimaging is vitally important to localize epileptic focus, maximize the preservation of unaffected areas, and optimize post-surgical outcomes. MR spectroscopic imaging (MRSI) is a promising modality to directly l ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment
SBC: PEPTIDE LOGIC LLC Topic: 104ABSTRACT: Migraine is a highly prevalent and disabling illness affecting about 47 million people in the US.1 First-line therapies consist of acute treatments such as non-steroidal anti-inflammatory drugs (NSAIDS), triptans, ditans or gepants.2 Unfortunately, acute therapies are often poorly effective in many patients. Only about 20-30% of patients achieve freedom of pain at 2 hours post treatment ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes
SBC: PEPTIDE LOGIC LLC Topic: 106ABSTRACT: Women are disproportionally impacted by functional pain syndromes (FPS), a large subgroup of pain conditions defined by the absence of a clear etiology or tissue injury. These syndromes have a high female:male prevalence ratio and include, but are not limited to, temporomandibular joint and muscle disorders (TMJD) (9:1 ratio), fibromyalgia (9:1 ratio), irritable bowel syndrome (IBS) (3:1 ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A Thermoreversible 3D Manufacturing Platform for Scalable Production of Dopaminergic Neurons for Parkinson's Disease Therapy
SBC: AXENT BIOSCIENCES INC. Topic: 106PROJECT SUMMARYParkinson's Disease (PD) affects more than 1 million adults in the U.S, and cell replacement therapy (CRT) using human embryonic stem cell (hESC) derived midbrain dopaminergic (DA) neurons has shown great promise in animal studies in alleviating symptoms of PD. However, current manufacturing strategies for cell therapies are constrained by the industry standard format – monolayer, ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Software Development--Drug Abuse Ethnographic Research
SBC: Applied Sciences Research Topic: N/ASince the mid-1970's, information on current and emerging drug abuse patterns and trends has been bepidemiologic data derived primarily from national probability samples and population-based surveys.however, there has been increasing interest in use of data generated through ethnographic methods toof drug abusing behavior. While surveys typically answer questions about the nature and extent of drt ...
SBIR Phase I 1995 Department of Health and Human Services -
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics
SBC: BUTO CORPORATION Topic: NIAAbstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also, there is an increasing perspective at NIA that Multi-target therapy m ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health